Staff Reports
The Food and Drug Administration has given the green light to Moderna’s mFlusiva — the first mRNA seasonal flu vaccine authorized in the United States. The FDA approved the shot for adults 50 to 64 with a full license and gave an accelerated approval for those 65 and older, while requiring a follow-up study. That’s the concrete development. The political drama around HHS Secretary Robert F. Kennedy Jr.’s outspoken skepticism of mRNA vaccines only makes the story louder.
FDA clears mFlusiva on data, not headlines
The agency’s vaccine advisers voted unanimously that the benefits outweigh the risks for adults 50–64 and supported accelerated approval for people 65 and up. The decision leaned on large phase‑3 trial data published in a top medical journal. The trial compared Moderna’s mRNA shot to a standard flu vaccine and found better protection with mFlusiva — roughly a 26.6% relative improvement by the trial’s measure. Side effects like sore arms and short‑term flu‑like symptoms were more common, but mostly mild to moderate.
Because the evidence in older adults relied on an accelerated pathway, Moderna must run a post‑marketing confirmatory study in the 65+ group to turn that accelerated approval into a full license. That’s normal regulatory practice. The FDA granted approval based on the trial results and set conditions to make sure the effectiveness claim is confirmed.
Politics tried to reroute science
Don’t miss the context: Secretary Robert F. Kennedy Jr. has been a prominent critic of mRNA technology and directed HHS to scale back many mRNA development projects. Earlier in the review process, FDA reviewers briefly issued a Refusal‑to‑File. That stirred headlines and fed the narrative that political pressure might upend a scientific review. But the advisory panel and the FDA looked at the randomized data and moved forward. In short: despite the political noise, the regulators approved an mRNA flu vaccine based on trial results.
What happens next: CDC, judges, and insurance
Approval by the FDA is a key step, but it isn’t the last. The CDC’s recommendation process usually decides who gets the shot routinely and whether insurers will cover it. That process is in limbo because court action has blocked the vaccine advisory panel from meeting under its current membership. The newly confirmed CDC director has vowed to “never betray the science,” which is comforting. Still, litigation and administrative delays mean widespread access and routine coverage could lag until those questions are resolved. Meanwhile, the mRNA platform’s real selling point — faster updates to match circulating strains — remains a practical advantage to watch.
Here’s the plain conservative takeaway: when science works, it should be allowed to work. The FDA’s approval of mFlusiva shows that solid trial data can overcome politics. That doesn’t mean the approved vaccine is a miracle cure — no flu shot is — but it does mean regulators followed evidence and set sensible guards, like a confirmatory study for older adults. If HHS leadership wants to steer vaccine policy, fine; just don’t sabotage the institutions that evaluate the data. Americans deserve clear, apolitical answers on health, not theater. Secretary Kennedy can keep tweeting his doubts from the sidelines while scientists do the heavy lifting — and we should judge the outcome by the facts, not the headlines.
